Clinical trial

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat…

NCT00281567 · Boehringer Ingelheim, Industry · Completed

Key facts

NCT number NCT00281567
Title Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)
Official title A Randomised, Double-blind, Double-dummy, Placebo-controlled, Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Two Doses [5 μg (2 Actuations of 2.5 μg) and 10 μg (2 Actuations of 5 μg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Tiotropium Inhalation…
Lead sponsor Boehringer Ingelheim, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Pulmonary Disease, Chronic Obstructive
Intervention type Device, Drug
Interventions Tiotropium, Respimat SMI, HandiHaler
Enrollment 76
Start date Aug 1, 2002
Primary completion Jul 1, 2003
First posted Jan 25, 2006
Last update posted Nov 1, 2013
Countries Belgium, Netherlands

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies